Immunotherapy and immunochemotherapy in combating visceral leishmaniasis

Area of Science:

• Parasitology
• Immunology
• Tropical Medicine

Background:

• Visceral leishmaniasis (VL) is a severe, fatal, vector-borne disease caused by *Leishmania* parasites, affecting tropical and subtropical regions.
• Current challenges include lack of vaccines, vector control issues, drug resistance, and HIV-VL co-infections, complicating treatment and control efforts.
• Existing treatments are often limited by efficacy, drug resistance, high cost, and prolonged hospitalization, necessitating novel therapeutic approaches.

Purpose of the Study:

• To review current Visceral Leishmaniasis (VL) treatment strategies.
• To emphasize the potential of biotherapy/immunotherapy as an alternative or adjunct to conventional chemotherapy.
• To highlight the importance of understanding VL pathogenesis and immunology for developing effective immunotherapeutic interventions.

Main Methods:

• Literature review focusing on Visceral Leishmaniasis (VL) treatment.
• Analysis of existing challenges in chemotherapy and the emergence of drug resistance.
• Exploration of preclinical and clinical studies on immunotherapy and immunochemotherapy for VL.

Main Results:

• Immunotherapy and immunochemotherapy have demonstrated improved therapeutic outcomes in preclinical studies.
• These approaches offer potential advantages such as limited side effects and reduced risk of drug resistance compared to conventional chemotherapy.
• A deeper understanding of VL pathogenesis and host immune responses is crucial for advancing these novel strategies.

Conclusions:

• There is an urgent need for safe and effective therapies to combat Visceral Leishmaniasis (VL).
• Biotherapy and immunotherapy present a viable alternative strategy with a favorable safety profile and reduced resistance potential.
• Further research into immunotherapy and immunochemotherapy is essential for improving VL treatment outcomes and disease control.